"There are two distinct streams of thought here: 1.) content concerning the results of past entities in which the CEO of BSSP has been involved and 2.) the market for Immunotherapy treatments for Cancer patients.
In addressing the first stream of thoughts on the past performance of the CEO I draw on the saying of Albert Ells that the best predictor of future behavior is past behavior.
“CBT is a blend of cognitive and behavioral therapies that help patients tune into their internal dialogue in order to change maladaptive thinking patterns. One type of CBT is rational emotive behavior therapy (REBT), which was developed by Albert Ellis. Ellis considers strong emotions to result from an interaction between events in the environment and our beliefs and expectations. Some of these beliefs can be too strong or rigid. For example, maintaining a belief that everyone should like you. With REBT, you would learn to change that belief so that it is less extreme and less likely to interfere with your life.”
Spending time projecting the results of the past performance of the CEO of BSSP definitely have strong emotions resulting from events in the market and their beliefs and expectations that have been formed based on their perception of slices of information from the past. The same clippings over and over 24/7. Some will hold on to their interpretations as if they were written by the finger of God in stone tablets when in fact they are just man’s interpretation.
We have all heard the story of the blind men trying to describe an elephant. Each blind man held on to a body part of the animal and each had a different perspective. The Blind man holding on to the leg had a different perception than the blind man holding the tail but each one firmly believed that he was right in his description.
What we continue to see is some are projecting on to the current market environment is their belief that the CEO is doing the same thing with BSSP as happened with the other entities that have been managed by Mr. Alexander. As PHX_INVEST pointed out all investments are risk reward propositions. The only thing certain about investing in sub-penny stocks is that you will make more bad decisions than good, but the one good decision will most often make up for all the bad ones and then some. If that was not the case then there would be no one here on this board.
It is the same with sub-penny Companies. undercapitalized, unproven technology or not fully developed technology all are conditons that no one can forsee success or failure in until it comes.
One thing that is not being pointed out is that Mr. Alexander seems to never give up on the entities that he has been involved in. He has failed while daring greatly rather than give up.
With REVE he took an entity dead in the water with no trading activity and a slew of issues overhanging the operations and through the acquisition of the Canteck Pharma Sub-license has breathed life into BSSP.
The CEO gave up control in order to facilitate the transaction. He is an employee now. Do you ever wonder why no one ever list their qualifications to grade others performance, it’s like listening to a plumber tell you how to perform brain surgery if you are not careful.
And Yes Virginia there is a Santa Claus, which brings me to the second stream of thought on this board – Immunotherapies are the apparent future of Cancer treatment. Doing a simple Google search you will find that several Immunotherapies have been approved over the last several months by the US FDA for the big pharmaceutical companies. In fact I read that 50% of all new cancer treatments being developed are Immunotherapies. Some are even charging as much as $25,000 a month for their treatments.
The current market for Cantech’s Cancer Applications appears to be, based on the Google search, in excess of $47.7 Billion per year worldwide and is one of the largest, fastest growing markets in the pharmaceutical industry. This markets greatest risk is purported to be pricing as a result of price cuts from payor’s, not erosion of prices from competition. This is actually a strength for Cantech as its product is reported to be cost effective to produce and may be effective as a periodic therapy instead of a daily one reducing the cost to the payors.
Yes Cantech Holdings does not own the Patents and it is only for the territory of Mexico but the Chairman is the Trustee for the owner of the Patent and the Science Officer is the developer of the treatment and the Patent. In addition the document says that the territory can be expanded. I foresee keeping it all in the family.
The sub-licensed Cancer Immunotherapy treatment is not currently in the process of trying to achieve FDA approval but the sister treatment licensed to the other public company is in or may have already completed its Phase III testing in Bulgaria. When successful completion has been achieved for the HIV/Aids product it will provide a road map for obtaining approval in the European Union for the Cancer Immunotherapy. In the meantime the import export license granted by the Mexican Government to Cantech and acquired by BSSP will provide an outlet for the use of the treatment in Mexican Hospitals. Once the Treatment achieves success in Mexico the proof will be in the pudding; Patients survive.
So how do you see the Elephant? Do you only see the beliefs that are to strong or rigid or do you see the whole animal. No one succeeds every time they strike out on a new venture, but they only fail when they stop getting up.
BSSP has a viable product, a market that is being developed and new and old management team that believes in the humanity of their treatment as well as the potential profit. Capturing only .001 of $47 billion market is revenue of $47 million yearly in a fast growing segment.
I think both stream of thought have merit but you have to see the whole package and realize it is a risk reward proposition that is based on the success of the treatment not the handling of issues that have existed prior to the transaction or the eventual results of failed business plans of other entities.
So lets not go after the french models and focus on who we came to the dance with."
From a good poster at IHUB
In addressing the first stream of thoughts on the past performance of the CEO I draw on the saying of Albert Ells that the best predictor of future behavior is past behavior.
“CBT is a blend of cognitive and behavioral therapies that help patients tune into their internal dialogue in order to change maladaptive thinking patterns. One type of CBT is rational emotive behavior therapy (REBT), which was developed by Albert Ellis. Ellis considers strong emotions to result from an interaction between events in the environment and our beliefs and expectations. Some of these beliefs can be too strong or rigid. For example, maintaining a belief that everyone should like you. With REBT, you would learn to change that belief so that it is less extreme and less likely to interfere with your life.”
Spending time projecting the results of the past performance of the CEO of BSSP definitely have strong emotions resulting from events in the market and their beliefs and expectations that have been formed based on their perception of slices of information from the past. The same clippings over and over 24/7. Some will hold on to their interpretations as if they were written by the finger of God in stone tablets when in fact they are just man’s interpretation.
We have all heard the story of the blind men trying to describe an elephant. Each blind man held on to a body part of the animal and each had a different perspective. The Blind man holding on to the leg had a different perception than the blind man holding the tail but each one firmly believed that he was right in his description.
What we continue to see is some are projecting on to the current market environment is their belief that the CEO is doing the same thing with BSSP as happened with the other entities that have been managed by Mr. Alexander. As PHX_INVEST pointed out all investments are risk reward propositions. The only thing certain about investing in sub-penny stocks is that you will make more bad decisions than good, but the one good decision will most often make up for all the bad ones and then some. If that was not the case then there would be no one here on this board.
It is the same with sub-penny Companies. undercapitalized, unproven technology or not fully developed technology all are conditons that no one can forsee success or failure in until it comes.
One thing that is not being pointed out is that Mr. Alexander seems to never give up on the entities that he has been involved in. He has failed while daring greatly rather than give up.
With REVE he took an entity dead in the water with no trading activity and a slew of issues overhanging the operations and through the acquisition of the Canteck Pharma Sub-license has breathed life into BSSP.
The CEO gave up control in order to facilitate the transaction. He is an employee now. Do you ever wonder why no one ever list their qualifications to grade others performance, it’s like listening to a plumber tell you how to perform brain surgery if you are not careful.
And Yes Virginia there is a Santa Claus, which brings me to the second stream of thought on this board – Immunotherapies are the apparent future of Cancer treatment. Doing a simple Google search you will find that several Immunotherapies have been approved over the last several months by the US FDA for the big pharmaceutical companies. In fact I read that 50% of all new cancer treatments being developed are Immunotherapies. Some are even charging as much as $25,000 a month for their treatments.
The current market for Cantech’s Cancer Applications appears to be, based on the Google search, in excess of $47.7 Billion per year worldwide and is one of the largest, fastest growing markets in the pharmaceutical industry. This markets greatest risk is purported to be pricing as a result of price cuts from payor’s, not erosion of prices from competition. This is actually a strength for Cantech as its product is reported to be cost effective to produce and may be effective as a periodic therapy instead of a daily one reducing the cost to the payors.
Yes Cantech Holdings does not own the Patents and it is only for the territory of Mexico but the Chairman is the Trustee for the owner of the Patent and the Science Officer is the developer of the treatment and the Patent. In addition the document says that the territory can be expanded. I foresee keeping it all in the family.
The sub-licensed Cancer Immunotherapy treatment is not currently in the process of trying to achieve FDA approval but the sister treatment licensed to the other public company is in or may have already completed its Phase III testing in Bulgaria. When successful completion has been achieved for the HIV/Aids product it will provide a road map for obtaining approval in the European Union for the Cancer Immunotherapy. In the meantime the import export license granted by the Mexican Government to Cantech and acquired by BSSP will provide an outlet for the use of the treatment in Mexican Hospitals. Once the Treatment achieves success in Mexico the proof will be in the pudding; Patients survive.
So how do you see the Elephant? Do you only see the beliefs that are to strong or rigid or do you see the whole animal. No one succeeds every time they strike out on a new venture, but they only fail when they stop getting up.
BSSP has a viable product, a market that is being developed and new and old management team that believes in the humanity of their treatment as well as the potential profit. Capturing only .001 of $47 billion market is revenue of $47 million yearly in a fast growing segment.
I think both stream of thought have merit but you have to see the whole package and realize it is a risk reward proposition that is based on the success of the treatment not the handling of issues that have existed prior to the transaction or the eventual results of failed business plans of other entities.
So lets not go after the french models and focus on who we came to the dance with."
From a good poster at IHUB
